Potential role for targeted therapy in muscle-invasive bladder cancer: Lessons from the cancer genome atlas and beyond

Urologic Clinics of North America

Volumn 42, Issue 2, 2015, Pages 201-215

  Mitra, Anirban P ^a   Lerner, Seth P ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trials; Mutation analysis; Prognosis; Targeted therapy; Urothelial carcinoma; Whole genome sequencing

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; BCG VACCINE; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DASATINIB; DN 24 02; DOVITINIB; ERDAFITINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; INFIGRATINIB; IPILIMUMAB; LAPATINIB; LETROZOLE; NIVOLUMAB; PACLITAXEL; PALBOCICLIB; PEMBROLIZUMAB; PROTEIN TYROSINE KINASE; RAS PROTEIN; SUNITINIB; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; IMMUNOLOGIC FACTOR; PROTEIN KINASE INHIBITOR;

ADJUVANT THERAPY; ARTICLE; BLADDER CARCINOGENESIS; BONE MARROW SUPPRESSION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESEARCH; CHEMOSENSITIVITY; CYSTECTOMY; DNA MICROARRAY; DRUG TARGETING; FGFR3 GENE; GENE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; MUSCLE INVASIVE BLADDER CANCER; ONCOGENE H RAS; OVERALL SURVIVAL; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; BOOK; GENETICS; HUMAN GENOME; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ATLASES AS TOPIC; GENOME, HUMAN; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; PROTEIN KINASE INHIBITORS; URINARY BLADDER NEOPLASMS;

EID: 84955400572     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2015.01.003     Document Type: Review

References (118)

1. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54(3):784-8.
2. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 2009;4:251-85.
3. Pasin E, Josephson DY, Mitra AP, et al. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 2008;10(1):31-43.
4. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24(35):5552-64.
5. Mitra AP, Bartsch CC, Cote RJ. Strategies for molecular expression profiling in bladder cancer. Cancer Metastasis Rev 2009;28(3-4):317-26.
6. Figueroa JD, Ye Y, Siddiq A, et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet 2014; 23(5):1387-98.
7. Nordentoft I, Lamy P, Birkenkamp-Demtröder K, et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep 2014;7(5):1649-63.
8. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507(7492): 315-22.
9. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499(7457): 214-8.
10. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505(7484): 495-501.
11. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39(Database Issue):D945-50.
12. Dyrskjøt L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33(1):90-6.
13. Volkmer JP, Sahoo D, Chin RK, et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A 2012;109(6):2078-83.
14. Mitra AP, Pagliarulo V, Yang D, et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 2009;27(24): 3929-37.
15. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013;22(4):795-803.
16. Sjödahl G, Lauss M, Lövgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012;18(12):3377-86.
17. ChoiW, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014;25(2):152-65.
18. Mitra AP, Skinner EC, Miranda G, et al. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer. BJU Int 2013; 111(2):240-8.
19. Ahmadi H, Mitra AP, Abdelsayed GA, et al. Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer. BJU Int 2013;111(4 Pt B):E167-72.
20. International Bladder Cancer Nomogram Consortium. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006;24(24):3967-72.
21. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006;12(22):6663-76.
22. Birkhahn M, Mitra AP, Cote RJ. Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev Anticancer Ther 2007; 7(12):1717-27.
23. Dyrskjøt L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005;11(11): 4029-36.
24. Wild PJ, Herr A, Wissmann C, et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005;11(12):4415-29.
25. Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005;11(11):4044-55.
26. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24(5): 778-89.
27. Kim WJ, Kim EJ, Kim SK, et al. Predictive value of progression-related gene classifier in primary nonmuscle invasive bladder cancer. Mol Cancer 2010; 9:3.
28. Kim WJ, Kim SK, Jeong P, et al. A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med 2011;17(5-6): 478-85.
29. Riester M, Taylor JM, Feifer A, et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 2012; 18(5):1323-33.
30. Mitra SA, Mitra AP, Triche TJ. A central role for long non-coding RNA in cancer. Front Genet 2012;3:17.
31. Mitra AP, Lam LL, Ghadessi M, et al. Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer. J Natl Cancer Inst 2014;106(11). pii:dju290.
32. Dyrskjøt L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscleinvasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007;13(12): 3545-51.
33. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012;30(10):1107-13.
34. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23(21):4602-8.
35. Rink M, Lee DJ, Kent M, et al. Predictors of cancerspecific mortality after disease recurrence following radical cystectomy. BJU Int 2013;111(3 Pt B): E30-6.
36. Mitra AP, Quinn DI, Dorff TB, et al. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int 2012;109(6): 846-54.
37. Chaux A, Cohen JS, Schultz L, et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol 2012;43(10):1590-5.
38. Wong YN, Litwin S, Vaughn D, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol 2012;30(28):3545-51.
39. Hussain M, Daignault S, Agarwal N, et al. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer 2014; 120(17):2684-93.
40. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 2010;105(3):317-21.
41. Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of cancer and leukemia group B (CALGB) 90102. Ann Oncol 2009;20(6):1074-9.
42. Pruthi RS, Nielsen M, Heathcote S, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int 2010;106(3):349-54.
43. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012;(4):CD006243.
44. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97.
45. Michaelson MD, Hu C, Pham HT, et al. The initial report of RTOG 0524: phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer. J Clin Oncol 2014;32(Suppl 4):LBA287.
46. Bajorin DF, Sharma P, Gomella LG, et al. NeuACT, a phase II, randomized, open-label trial of DN24-02: updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER21 urothelial cancer. J Clin Oncol 2014;32(Suppl 4):296.
47. Wülfing C, Machiels JP, Richel DJ, et al. A singlearm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009;115(13):2881-90.
48. Bartsch G, Mitra AP, Cote RJ. Expression profiling for bladder cancer: strategies to uncover prognostic factors. Expert Rev Anticancer Ther 2010; 10(12):1945-54.
49. Rebouissou S, Herault A, Letouze E, et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J Pathol 2012;227(3):315-24.
50. Tomlinson DC, Baldo O, Harnden P, et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007;213(1):91-8.
51. Milowsky MI, Dittrich C, Durán I, et al. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer 2014;50(18):3145-52.
52. Bahleda R, Dienstmann R, Adamo B, et al. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014; 32(Suppl 5):2501.
53. Sequist LV, Cassier P, Varga A, et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res 2014;74(Suppl 19):CT326.
54. Youssef RF, Mitra AP, Bartsch G Jr, et al. Molecular targets and targeted therapies in bladder cancer management. World J Urol 2009;27(1):9-20.
55. Sonpavde G, Jian W, Liu H, et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009;27(4):391-9.
56. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010;28(8):1373-9.
57. Galsky MD, Hahn NM, Powles T, et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 2013;11(2):175-81.
58. Hahn NM, Daneshmand S, Posadas EM, et al. A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial. J Clin Oncol 2012;30(Suppl 15):4586.
59. Knudsen B, Hahn NM, Daneshmand S, et al. Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). J Clin Oncol 2014;32(Suppl 4):324.
60. Houédé N, Pourquier P. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers. Pharmacol Ther 2015;145C:1-18.
61. Gomez-Pinillos A, Ferrari AC. mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am 2012;26(3):483-505.
62. Seront E, Rottey S, Sautois B, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012;23(10):2663-70.
63. Milowsky MI, Iyer G, Regazzi AM, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013;112(4):462-70.
64. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338(6104):221.
65. Mitra AP, Lin H, Cote RJ, et al. Biomarker profiling for cancer diagnosis, prognosis and therapeutic management. Natl Med J India 2006;18(6):304-12.
66. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004;22(6):1014-24.
67. Shariat SF, Lotan Y, Karakiewicz PI, et al. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol 2009;182(3):907-13.
68. Mitra AP, Castelao JE, Hawes D, et al. Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer 2013;119(4):756-65.
69. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331(19):1259-64.
70. Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011;29(25): 3443-9.
71. Mitra AP, Lin H, Datar RH, et al. Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer 2006;5(1):67-77.
72. Mitra AP, Birkhahn M, Cote RJ. p53 and retinoblastoma pathways in bladder cancer. World J Urol 2007;25(6):563-71.
73. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008;112(2):315-25.
74. Mitra AP, Hansel DE, Cote RJ. Prognostic value of cell-cycle regulation biomarkers in bladder cancer. Semin Oncol 2012;39(5):524-33.
75. Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010;183(1):68-75.
76. Mitra AP, Datar RH, Cote RJ. Molecular staging of bladder cancer. BJU Int 2005;96(1):7-12.
77. Finn RS, Crown JP, Lang I, et al. Final results of a randomized phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER1/HER2-advanced breast cancer (PALOMA-1; TRIO-18). Cancer Res 2014; 74(Suppl 19):CT101.
78. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87(21):1603-12.
79. Birkhahn M, Mitra AP, Williams AJ, et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 2010;57(1):12-20.
80. Mitra AP, Almal AA, George B, et al. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer 2006;6:159.
81. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 2011;29(12):1525-30.
82. Siefker-Radtke AO, Kamat AM, Corn PG, et al. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: results from a phase II trial at the M. D. Anderson Cancer Center. J Clin Oncol 2012;30(Suppl 5):261.
83. Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009;115(18):4090-5.
84. Sridhar SS, Winquist E, Eisen A, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs 2011;29(5):1045-9.
85. Choueiri TK, Ross RW, Jacobus S, et al. Doubleblind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinumpretreated metastatic urothelial cancer. J Clin Oncol 2012;30(5):507-12.
86. Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 2012;13(8):810-6.
87. Azad AA, Zoubeidi A, Gleave ME, et al. Targeting heat shock proteins in metastatic castrationresistant prostate cancer. Nat Rev Urol 2015; 12(1):26-36.
88. Katsogiannou M, Andrieu C, Rocchi P. Heat shock protein 27 phosphorylation state is associated with cancer progression. Front Genet 2014;5:346.
89. Hayashi N, Peacock JW, Beraldi E, et al. Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death Differ 2012; 19(6):990-1002.
90. Kamada M, So A, Muramaki M, et al. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007;6(1): 299-308.
91. Hadaschik BA, Jackson J, Fazli L, et al. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. BJU Int 2008;102(5):610-6.
92. OncoGenex announces results from the phase 2 Borealis-1™ trial of apatorsen in the treatment of metastatic bladder cancer. 2014. Available at: www.prnewswire.com. Accessed January 8, 2015.
93. Nishiyama T, Tachibana M, Horiguchi Y, et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 2001;7(1):23-31.
94. Marchand M, Punt CJ, Aamdal S, et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003;39(1):70-7.
95. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271(5256):1734-6.
96. Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010;16(10):2861-71.
97. Dong H, Strome SE, Salomao DR, et al. Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793-800.
98. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26): 2455-65.
99. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515(7528):558-62.
100. Netto GJ, Epstein JI. Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology 2010;42(4):384-94.
101. Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012;62(3):523-33.
102. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 2005;48(2):202-5 [discussion: 205-6].
103. Cote RJ, Esrig D, Groshen S, et al. p53 and treatment of bladder cancer. Nature 1997;385(6612):123-5.
104. Waldman T, Lengauer C, Kinzler KW, et al. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381(6584):713-6.
105. Mitra AP, Cote RJ. Searching for novel therapeutics and targets: insights from clinical trials. Urol Oncol 2007;25(4):341-3.
106. Als AB, Dyrskjøt L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007;13(15 Pt 1):4407-14.
107. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvantchemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005;11(7):2625-36.
108. Takata R, Katagiri T, Kanehira M, et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci 2007;98(1):113-7.
109. Kato Y, Zembutsu H, Takata R, et al. Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling. Exp Ther Med 2011;2(1):47-56.
110. Iwasaki K, Obara W, Kato Y, et al. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer. Jpn J Clin Oncol 2013;43(2):193-9.
111. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007; 18(3):522-8.
112. Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010;12(8): 628-36.
113. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatinbased chemotherapy in bladder cancer. Ann Oncol 2011;22(1):139-44.
114. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007;104(32):13086-91.
115. Williams PD, Cheon S, Havaleshko DM, et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 2009;69(21):8302-9.
116. Abrams J, Conley B, Mooney M, et al. National Cancer Institute's precision medicine initiatives for the new National Clinical Trials Network. In: American Society of Clinical Oncology educational book. Alexandria (VA): American Society of Clinical Oncology; 2014. p. 71-6.
117. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349(9): 859-66.
118. Lerner SP. Targeted therapies for metastatic bladder cancer. J Urol 2015;193(1):8-9.